Intraperitoneal Paclitaxel for Appendiceal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you are on any investigational agents, you cannot participate in the trial.
Is intraperitoneal paclitaxel safe for humans?
Paclitaxel has been used in humans for various cancers, but it can cause side effects like hypersensitivity reactions (allergic reactions), myelosuppression (reduced bone marrow activity), and neurotoxicity (nerve damage). Intraperitoneal administration has shown safety in trials for colorectal cancer, but patients should be monitored for these side effects.12345
How is the drug paclitaxel unique for treating appendiceal cancer?
Paclitaxel is unique for treating appendiceal cancer because it is delivered directly into the peritoneal cavity (the space in the abdomen that contains the intestines and other organs), which is where this type of cancer often spreads. This method allows for higher concentrations of the drug at the tumor site with fewer side effects compared to traditional intravenous administration.678910
What evidence supports the effectiveness of the drug paclitaxel for treating appendiceal cancer?
Who Is on the Research Team?
Beth Helmink, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with metastatic appendiceal adenocarcinoma, which is a type of cancer that affects the appendix and has spread to other areas. The study aims to find participants who can receive paclitaxel directly into their abdominal cavity.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase I Treatment
Participants receive intraperitoneal paclitaxel to determine the maximum tolerated dose, administered every 14 days
Phase II Treatment
Participants receive paclitaxel at the recommended dose determined in Phase I
Follow-up
Participants are monitored for safety, effectiveness, and progression-free survival after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Paclitaxel
Paclitaxel is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor